Ovarian and Endometrial Cancer — An Interview with Dr Shannon Westin on the Current Management Paradigm
Research To Practice | Oncology Videos · Dr. Neil Love
August 20, 202552m 35s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Featuring an interview with Dr Shannon N Westin, including the following topics:
- Biomarker testing and utility in ovarian cancer (OC) (0:00)
- Selection of a PARP inhibitor for the treatment of OC (9:18)
- Addition of immunotherapy to up-front treatment of OC (15:50)
- Utility of minimal residual disease and circulating tumor DNA assays in OC (17:10)
- Selection of treatment for recurrent OC (21:46)
- Clinical decision-making involved with PARP inhibitors for endometrial cancer (EC) (28:22)
- Adjuvant therapy for EC (32:28)
- Utility of lenvatinib/pembrolizumab in EC (35:08)
- Clinical findings supporting the potential use of selinexor for EC (39:42)
- Key findings involving trastuzumab deruxtecan (T-DXd) for HER2-positive gynecologic cancers (43:22)
- Management of adverse effects associated with T-DXd (49:49)